The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Holding(s) in Company

17 Feb 2017 14:04

RNS Number : 2167X
Immupharma PLC
17 February 2017
 

17 FEBRUARY 2017

 

 

 

NOTIFICATION OF INTEREST BY LEGAL & GENERAL

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 3,774,714 million Ordinary Shares in the capital of the Company.

 

Full disclosure of the TR1 is shown below:

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

ImmuPharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

Legal & General Assurance Society Limited (LGAS)

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

15 February 2017

6. Date on which issuer notified:

16 February 2017

7. Threshold(s) that is/are crossed orreached:

 

L&G (Below 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.10

3,774,714

 Below 3%

 Below 3%

-

Below 3%

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 Below 3%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( Below 5% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  124,638,362

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

 

 

 

 

-Ends-

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLZDLFFDLFBBBF

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.